P2Y12 inhibitor monotherapy after coronary revascularisation has also been assessed in several trials, with one meta-analysis recently establishing that P2Y12 inhibitor monotherapy was associated with a similar risk of death, MI, or stroke and lower risk of major bleeding as DAPT, suggesting that shortening DAPT to 1 to 3 months post-PCI could be effective and safe [40]. Here, P2RY12 is linked to Stroke.